Tags

Type your tag names separated by a space and hit enter

Potential Antiviral Options against SARS-CoV-2 Infection.
Viruses. 2020 06 13; 12(6)V

Abstract

As of June 2020, the number of people infected with severe acute respiratory coronavirus 2 (SARS-CoV-2) continues to skyrocket, with more than 6.7 million cases worldwide. Both the World Health Organization (WHO) and United Nations (UN) has highlighted the need for better control of SARS-CoV-2 infections. However, developing novel virus-specific vaccines, monoclonal antibodies and antiviral drugs against SARS-CoV-2 can be time-consuming and costly. Convalescent sera and safe-in-man broad-spectrum antivirals (BSAAs) are readily available treatment options. Here, we developed a neutralization assay using SARS-CoV-2 strain and Vero-E6 cells. We identified the most potent sera from recovered patients for the treatment of SARS-CoV-2-infected patients. We also screened 136 safe-in-man broad-spectrum antivirals against the SARS-CoV-2 infection in Vero-E6 cells and identified nelfinavir, salinomycin, amodiaquine, obatoclax, emetine and homoharringtonine. We found that a combination of orally available virus-directed nelfinavir and host-directed amodiaquine exhibited the highest synergy. Finally, we developed a website to disseminate the knowledge on available and emerging treatments of COVID-19.

Authors+Show Affiliations

Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, 7028 Trondheim, Norway.Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, 7028 Trondheim, Norway.Department of Medical Microbiology, St. Olavs Hospital, 7006 Trondheim, Norway. Department of Immunology and Transfusion Medicine, St. Olavs Hospital, 7006 Trondheim, Norway.Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, 7028 Trondheim, Norway.Institute of Technology, University of Tartu, 50090 Tartu, Estonia.Institute of Genomics Core Facility, University of Tartu, 51010 Tartu, Estonia.Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, 7028 Trondheim, Norway.Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, 7028 Trondheim, Norway.Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, 7028 Trondheim, Norway.Department of Medical Microbiology, St. Olavs Hospital, 7006 Trondheim, Norway.Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, 7028 Trondheim, Norway.Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, 7028 Trondheim, Norway.Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, 7028 Trondheim, Norway.Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, 7028 Trondheim, Norway.Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, 7028 Trondheim, Norway.Institute of Technology, University of Tartu, 50090 Tartu, Estonia.Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, 7028 Trondheim, Norway. Department of Medical Microbiology, St. Olavs Hospital, 7006 Trondheim, Norway.Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, 7028 Trondheim, Norway. Department of Medical Microbiology, St. Olavs Hospital, 7006 Trondheim, Norway.Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, 7028 Trondheim, Norway.Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, 7028 Trondheim, Norway. Institute of Technology, University of Tartu, 50090 Tartu, Estonia.

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

32545799

Citation

Ianevski, Aleksandr, et al. "Potential Antiviral Options Against SARS-CoV-2 Infection." Viruses, vol. 12, no. 6, 2020.
Ianevski A, Yao R, Fenstad MH, et al. Potential Antiviral Options against SARS-CoV-2 Infection. Viruses. 2020;12(6).
Ianevski, A., Yao, R., Fenstad, M. H., Biza, S., Zusinaite, E., Reisberg, T., Lysvand, H., Løseth, K., Landsem, V. M., Malmring, J. F., Oksenych, V., Erlandsen, S. E., Aas, P. A., Hagen, L., Pettersen, C. H., Tenson, T., Afset, J. E., Nordbø, S. A., Bjørås, M., & Kainov, D. E. (2020). Potential Antiviral Options against SARS-CoV-2 Infection. Viruses, 12(6). https://doi.org/10.3390/v12060642
Ianevski A, et al. Potential Antiviral Options Against SARS-CoV-2 Infection. Viruses. 2020 06 13;12(6) PubMed PMID: 32545799.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Potential Antiviral Options against SARS-CoV-2 Infection. AU - Ianevski,Aleksandr, AU - Yao,Rouan, AU - Fenstad,Mona Høysæter, AU - Biza,Svetlana, AU - Zusinaite,Eva, AU - Reisberg,Tuuli, AU - Lysvand,Hilde, AU - Løseth,Kirsti, AU - Landsem,Veslemøy Malm, AU - Malmring,Janne Fossum, AU - Oksenych,Valentyn, AU - Erlandsen,Sten Even, AU - Aas,Per Arne, AU - Hagen,Lars, AU - Pettersen,Caroline H, AU - Tenson,Tanel, AU - Afset,Jan Egil, AU - Nordbø,Svein Arne, AU - Bjørås,Magnar, AU - Kainov,Denis E, Y1 - 2020/06/13/ PY - 2020/05/14/received PY - 2020/06/09/revised PY - 2020/06/11/accepted PY - 2020/6/18/entrez PY - 2020/6/18/pubmed PY - 2020/7/1/medline KW - antiviral drug combinations KW - antivirals KW - broad-spectrum antivirals JF - Viruses JO - Viruses VL - 12 IS - 6 N2 - As of June 2020, the number of people infected with severe acute respiratory coronavirus 2 (SARS-CoV-2) continues to skyrocket, with more than 6.7 million cases worldwide. Both the World Health Organization (WHO) and United Nations (UN) has highlighted the need for better control of SARS-CoV-2 infections. However, developing novel virus-specific vaccines, monoclonal antibodies and antiviral drugs against SARS-CoV-2 can be time-consuming and costly. Convalescent sera and safe-in-man broad-spectrum antivirals (BSAAs) are readily available treatment options. Here, we developed a neutralization assay using SARS-CoV-2 strain and Vero-E6 cells. We identified the most potent sera from recovered patients for the treatment of SARS-CoV-2-infected patients. We also screened 136 safe-in-man broad-spectrum antivirals against the SARS-CoV-2 infection in Vero-E6 cells and identified nelfinavir, salinomycin, amodiaquine, obatoclax, emetine and homoharringtonine. We found that a combination of orally available virus-directed nelfinavir and host-directed amodiaquine exhibited the highest synergy. Finally, we developed a website to disseminate the knowledge on available and emerging treatments of COVID-19. SN - 1999-4915 UR - https://www.unboundmedicine.com/medline/citation/32545799/Potential_Antiviral_Options_against_SARS_CoV_2_Infection_ L2 - https://www.mdpi.com/resolver?pii=v12060642 DB - PRIME DP - Unbound Medicine ER -